Esco VacciXcell is a global technological alliance on a mission for worldwide human and animal immunization for human and food safety. The company firmly believes that prevention is better than cure. This bioprocessing division for Esco Lifesciences Group was established with the vision in mind to solve the challenges of being able to manufacture large volumes of vaccines, cell/regenerative therapeutics in a cost-effective manner in the event of a pandemic or outbreak.
The COVID-19 outbreak caused Health authorities around the world to be on high alert due to the respiratory illness caused by this 2019 novel coronavirus (2019-nCoV). With more than 9,220,300 confirmed cases and more than 474,998 deaths worldwide as of June 23, 2020, researchers are in a race to create a vaccine with a shorter production timeline.
Getting vaccinated helps and trains the body’s immune system to fight this disease and prevent it from spreading. Scientists can develop a potential vaccine with the help of the information released about the virus’ genetic code. Some types of vaccines that have the potential to become major coronavirus vaccines include: Viral Vectors, DNA or RNA Vaccine Technology, Protein-based and Live-attenuated Vaccine Technologies
Esco VacciXcell provides an ideal bioprocessing platform and tools for high cell/product yield at a low cost for various applications such as vaccines and cell therapy.
Esco VacciXcell’ core Tide Motion technology offers bioreactors (CelCradle™ and TideXcell™) that are scalable high-density adherent cell culture production platforms, which can be used for manufacturing viral vectors. Vector production in its microporous BioNOC™ II carriers are 10 times or more efficient as compared with traditional 2D systems like cell factories. Although suspension cell-based cell cultures provide true scalability from small scale to large scale, not all expression systems which are adherent in nature allow adaptation to a serum-free suspension culture whilst maintaining high productivity.
Naked plasmid DNA (pDNA) can be grown under standard fermentation conditions and manufactured in large stirred tank bioreactors. Esco VacciXcell offers stirred tank bioreactors from 5 L all the way to 2,000 L production scale. The StirCradle™ stirred tank bioreactor combines vessel, workbench, controller, and peristaltic pumps into one integrated system. Process modes such as batch and fed-batch, which is important in manufacturing DNA vaccines, are available making it ideal for research and development. The StirCradle™ PRO is a fully automated stirred tank bioreactor for large scale expansion of bacterial cells.
E. coli, a commonly used bacterial cell for expressing vaccine antigens, is well-defined and a high yielding host system. This bacterium can be produced in large colonies in stirred tank bioreactors like StirCradle™ and StirCradle™ PRO. As bacteria are easily manipulated and cultured, they are also advantageous for those types of recombinant vaccines that do not require significant post-translational modifications.
It has always been Esco’s mission to provide its clients with a complete turnkey manufacturing solution from Discovery to Delivery for all their bioprocessing needs. The company does this by ensuring a high quality, efficient, dependable and cost-effective product line. Flatten the curve with Esco, your partner in Biosafety bioprocessing – Improving lives through science.
Lizemarie.chapman@escoglobal.com
+27 11 314 3184
www.escoglobal.com
